These experimental data showed that adenovirus-mediated siRNA targeting Bcl-xL could increase the in vivo radiosensitivity of CRC cells, which showed that combined Bcl-xL downregulation with radiotherapy could lead to a stronger anti-tumor effect for human CRC. The gene discussed is BCL2L1; the disease is colorectal carcinoma.